Literature DB >> 22038740

Role of microRNAs in the reperfused myocardium towards post-infarct remodelling.

Hongyan Zhu1, Guo-Chang Fan.   

Abstract

Myocardial ischaemia/reperfusion (I/R)-induced remodelling generally includes cell death (necrosis and apoptosis), myocyte hypertrophy, angiogenesis, cardiac fibrosis, and myocardial dysfunction. It is becoming increasingly clear that microRNAs (miRNAs or miRs), a group of highly conserved small (∼18-24 nucleotide) non-coding RNAs, fulfil specific functions in the reperfused myocardium towards post-infarct remodelling. While miR-21, -133, -150, -195, and -214 regulate cardiomyocyte hypertrophy, miR-1/-133 and miR-208 have been elucidated to influence myocardial contractile function. In addition, miR-21, -24, -133, -210, -494, and -499 appear to protect myocytes against I/R-induced apoptosis, whereas miR-1, -29, -199a, and -320 promote apoptosis. Myocardial fibrosis can be regulated by the miR-29 family and miR-21. Moreover, miR-126 and miR-210 augment I/R-induced angiogenesis, but miR-24, -92a, and -320 suppress post-infarct neoangiogenesis. In this review, we summarize the latest advances in the identification of myocardial ischaemia-associated miRNAs and their functional significance in the modulation of I/R-triggered remodelling. Controversial effects of some miRNAs in post-infarct remodelling will be also discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22038740      PMCID: PMC3331611          DOI: 10.1093/cvr/cvr291

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  99 in total

1.  NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.

Authors:  Konstantin D Taganov; Mark P Boldin; Kuang-Jung Chang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-02       Impact factor: 11.205

2.  MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction.

Authors:  Emanuela Bostjancic; Nina Zidar; Dusan Stajer; Damjan Glavac
Journal:  Cardiology       Date:  2009-12-21       Impact factor: 1.869

Review 3.  MicroRNA-21 in cardiovascular disease.

Authors:  Yunhui Cheng; Chunxiang Zhang
Journal:  J Cardiovasc Transl Res       Date:  2010-05-01       Impact factor: 4.132

4.  Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy.

Authors:  Mariko Tatsuguchi; Hee Young Seok; Thomas E Callis; J Michael Thomson; Jian-Fu Chen; Martin Newman; Mauricio Rojas; Scott M Hammond; Da-Zhi Wang
Journal:  J Mol Cell Cardiol       Date:  2007-04-14       Impact factor: 5.000

Review 5.  Why do we still not have cardioprotective drugs?

Authors:  James M Downey; Michael V Cohen
Journal:  Circ J       Date:  2009-06-09       Impact factor: 2.993

Review 6.  Role of apoptosis in reperfusion injury.

Authors:  Frank Eefting; Benno Rensing; Jochem Wigman; Willem Jan Pannekoek; Wai Ming Liu; Maarten Jan Cramer; Daniel J Lips; Pieter A Doevendans
Journal:  Cardiovasc Res       Date:  2004-02-15       Impact factor: 10.787

Review 7.  Role of microRNAs in vascular diseases, inflammation, and angiogenesis.

Authors:  Carmen Urbich; Angelika Kuehbacher; Stefanie Dimmeler
Journal:  Cardiovasc Res       Date:  2008-06-11       Impact factor: 10.787

8.  MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice.

Authors:  Angelika Bonauer; Guillaume Carmona; Masayoshi Iwasaki; Marina Mione; Masamichi Koyanagi; Ariane Fischer; Jana Burchfield; Henrik Fox; Carmen Doebele; Kisho Ohtani; Emmanouil Chavakis; Michael Potente; Marc Tjwa; Carmen Urbich; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Science       Date:  2009-05-21       Impact factor: 47.728

9.  MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells.

Authors:  Céline Sabatel; Ludovic Malvaux; Nicolas Bovy; Christophe Deroanne; Vincent Lambert; Maria-Luz Alvarez Gonzalez; Alain Colige; Jean-Marie Rakic; Agnès Noël; Joseph A Martial; Ingrid Struman
Journal:  PLoS One       Date:  2011-02-10       Impact factor: 3.240

10.  Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis.

Authors:  Coen van Solingen; Leonard Seghers; Roel Bijkerk; Jacques M G J Duijs; Marko K Roeten; Annemarie M van Oeveren-Rietdijk; Hans J Baelde; Matthieu Monge; Joost B Vos; Hetty C de Boer; Paul H A Quax; Ton J Rabelink; Anton Jan van Zonneveld
Journal:  J Cell Mol Med       Date:  2009-08       Impact factor: 5.310

View more
  71 in total

Review 1.  Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction.

Authors:  Christian Schulte; Dirk Westermann; Stefan Blankenberg; Tanja Zeller
Journal:  World J Cardiol       Date:  2015-12-26

2.  β-arrestin-biased agonism of β-adrenergic receptor regulates Dicer-mediated microRNA maturation to promote cardioprotective signaling.

Authors:  Jian-Peng Teoh; Ahmed S Bayoumi; Tatsuya Aonuma; Yanyan Xu; John A Johnson; Huabo Su; Neal L Weintraub; Yaoliang Tang; Il-Man Kim
Journal:  J Mol Cell Cardiol       Date:  2018-04-06       Impact factor: 5.000

3.  Integrated microRNA and mRNA responses to acute human left ventricular ischemia.

Authors:  Louis A Saddic; Tzuu-Wang Chang; Martin I Sigurdsson; Mahyar Heydarpour; Benjamin A Raby; Stanton K Shernan; Sary F Aranki; Simon C Body; Jochen D Muehlschlegel
Journal:  Physiol Genomics       Date:  2015-07-14       Impact factor: 3.107

Review 4.  MicroRNAs as Potential Pharmaco-targets in Ischemia-Reperfusion Injury Compounded by Diabetes.

Authors:  Hassan Dehaini; Hussein Awada; Ahmed El-Yazbi; Fouad A Zouein; Khodr Issa; Assaad A Eid; Maryam Ibrahim; Adnan Badran; Elias Baydoun; Gianfranco Pintus; Ali H Eid
Journal:  Cells       Date:  2019-02-12       Impact factor: 6.600

5.  Merely miR210 in mesenchymal stem cells--one size fits all.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2012-09       Impact factor: 4.599

Review 6.  miR-21 in ischemia/reperfusion injury: a double-edged sword?

Authors:  Xialian Xu; Alison J Kriegel; Xiaoyan Jiao; Hong Liu; Xiaowen Bai; Jessica Olson; Mingyu Liang; Xiaoqiang Ding
Journal:  Physiol Genomics       Date:  2014-08-26       Impact factor: 3.107

7.  Cardiac fibroblasts in pressure overload hypertrophy: the enemy within?

Authors:  Nenad Bursac
Journal:  J Clin Invest       Date:  2014-06-17       Impact factor: 14.808

8.  Protective effect of miR-20a against hypoxia/reoxygenation treatment on cardiomyocytes cell viability and cell apoptosis by targeting TLR4 and inhibiting p38 MAPK/JNK signaling.

Authors:  Xin-Yu Gong; Yun Zhang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2019-08-23       Impact factor: 2.416

9.  Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology.

Authors:  Warren D Gray; Kristin M French; Shohini Ghosh-Choudhary; Joshua T Maxwell; Milton E Brown; Manu O Platt; Charles D Searles; Michael E Davis
Journal:  Circ Res       Date:  2014-10-24       Impact factor: 17.367

10.  miR-539 as a key negative regulator of the MEK pathway in myocardial infarction.

Authors:  J Hui; W Huishan; L Tao; Y Zhonglu; Z Renteng; H Hongguang
Journal:  Herz       Date:  2016-12-15       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.